Efficacy of prolonged tenofovir therapy on Hepatitis delta in HIV-infected patients

AIDS

Volumn 28, Issue 16, 2014, Pages 2389-2394

  Soriano, Vincent ^a   Vispo, Eugenia ^a   Sierra Enguita, Rocío ^a   De Mendoza, Carmen ^b   Fernández Montero, José V ^a   Labarga, Pablo ^a   Barreiro, Pablo ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Elastometry; Hepatitis delta; HIV; Liver fibrosis; Tenofovir

Indexed keywords

DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; RALTEGRAVIR; TENOFOVIR; VIRUS DNA; VIRUS RNA; ADENINE; ANTIVIRUS AGENT; PHOSPHONIC ACID DERIVATIVE;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); DELTA AGENT HEPATITIS; DRUG EFFICACY; DRUG EXPOSURE; ELASTOGRAPHY; FEMALE; FOLLOW UP; GENERAL PATHOLOGICAL PARAMETERS; GENOTYPE; HEPATITIS DELTA VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIVER FIBROSIS; LIVER STIFFNESS; LONG TERM EXPOSURE; MALE; MIXED INFECTION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; VIREMIA; VIRUS INHIBITION; ANALOGS AND DERIVATIVES; BLOOD; COMPLICATION; HEPATITIS D, CHRONIC; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; VIRUS LOAD;

ADENINE; ADULT; ANTIVIRAL AGENTS; HEPATITIS D, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RETROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84916636198     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000417     Document Type: Article

References (43)

1. Taylor J. Replication of the hepatitis delta virus RNA genome. Adv Virus Res 2009;74:103-121.
2. Tseng C, Lai M. Hepatitis delta virus RNA replication. Viruses 2009;1:818-831.
3. Rizzetto M, Hepatitis D. Thirty years after. J Hepatol 2009;50:1043-1050.
4. Hughes S, Wedemeyer H, Harrison P. Hepatitis delta virus. Lancet 2011;378:73-85.
5. Calle-Serrano B, Manns M, Wedemeyer H. Hepatitis delta and HIV infection. Sem Liver Dis 2012;32:120-129.
6. Wedemeyer H. Hepatitis D revival. Liver Int 2011;31(Suppl 1):140-144.
7. Rizzetto M, Alavian SM. Hepatitis delta: the rediscovery. Clin Liver Dis 2013;17:475-487.
8. Lavanchy D. Viral hepatitis: global goals for vaccination. J Clin Virol 2012;55:296-302.
9. Rizzetto M, Hepatitis D. Clinical features and therapy. Dig Dis 2010;28:139-143.
10. Niro G, Smedile A. Current concept in the pathophysiology of hepatitis delta infection. Curr Infect Dis Rep 2012;14:9-14.
11. Niro G, Ciancio A, Gaeta G, Smedile A, Marrone A, Olivero A, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006;44:713-720.
12. Yurdayd1/2n C, Idilman R, Bozkaya H, Bozdayi A. Natural history and treatment of chronic delta hepatitis. J Viral Hepat 2010;17:749-756.
13. Romeo R, Colombo M. Treatment of chronic hepatitis delta: mission impossible? Gastroenterology 2011;141:2268-2271.
14. Yurdaydin C. Treatment of chronic delta hepatitis. Sem Liver Dis 2012;32:237-244.
15. Rizzetto M. Current management of delta hepatitis. Liver Int 2013;33:195-197.
16. Lamers M, Kirgiz Ö, Heidrich B, Wedemeyer H, Drenth J. Interferon-(for patients with chronic hepatitis delta: a systematic review of randomized clinical trials. Antivir Ther 2012;17:1029-1037.
17. Heidrich B, Manns M, Wedemeyer H. Treatment options for hepatitis delta virus infection. Curr Infect Dis Reports 2013;15:31-38.
18. Glenn J. Prenylation of HDAg and antiviral drug development. Curr Top Microbiol Immunol 2006;307:133-149.
19. Ciancio A, Rizzetto M. Chronic hepatitis D at a standstill: where do we go from here? Nat Rev Gastroenterol Hepatol 2014;11:68-71.
20. Chang S-Y, Yang C-L, Ko W-S, Liu W, Lin C, Wu C, et al. Molecular epidemiology of hepatitis D virus infection among injecting drug users with and without HIV infection in Taiwan. J Clin Microbiol 2011;49:1083-1089.
21. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350.
22. Vergara S, Macías J, Rivero A, Gutierrez-Valencia A, Gonzalez-Serrano M, Merino D, et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007;45:969-974.
23. Soriano V, Barreiro P, Sherman K. The changing epidemiology of liver disease in HIV patients. AIDS Rev 2013;15:25-31.
24. Sheng W, Hung C, Kao J, Chang S, Chen M, Hsieh S, et al. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study. Clin Infect Dis 2007;44:988-995.
25. Konopnicki D, Mocroft A, De Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005;19:593-601.
26. Soriano V, Grint D, D'Arminio Monforte A, Horban A, Leen C, Poveda E, et al. Hepatitis delta in HIV-infected individuals in Europe. AIDS 2011;25:1987-1992.
27. Niro G, Ciancio A, Tillman H, Lagget M, Olivero A, Perri F, et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther 2005;22:227-232.
28. Wedemeyer H, Yurdaydin C, Dalekos G, Erhardt A, Çakaloglu Y, Degertekin H, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011;364:322-331.
29. Babiker Z, Hogan C, Ustianowski A, Wilkins E. Does interferonsparing tenofovir-based therapy have a role in the management of severe acute hepatitis delta superinfection? J Med Microbiol 2012;61:1780-1783.
30. Sheldon J, Ramos B, Toro C, Rios P, Martinez-Alarcon J, Bottecchia M, et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replicationin HIV-HBV-HDV-coinfected patients? Antivir Ther 2008;13:97-102.
31. Mansour W, Ducancelle A, Le Gal F, Le Guillou-Guillemette H, Abgueguen P, Pivert A, et al. Resolution of chronic hepatitis delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine. J Clin Virol 2010;47:97-99.
32. Boyd A, Miailhes P, Brichier S, Scholtes C, Maylin S, Delaugerre C, et al. Effect of tenofovir with and without interferon on hepatitis delta virus replication in HIV-HBV-HDV-infected patients. AIDS Res Human Retroviruses 2013;29:1535-1540.
33. Wedemeyer H, Port K, Heidrich B, Hardtke S, Manns M, Yurdaydin C, et al. 96 weeks of pegylated interferon alpha-2a plus tenofovir or placebo for the treatmentof hepatitis delta: the HIDIT-2 study [abstract 31]. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 5-8 November 2013, Washington, DC. 2013.
34. Zachou K, Yurdaydin C, Drebber U, Dalekos G, Erhardt A, Çakaloglu Y, et al. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int 2010;30:430-437.
35. Martín-Carbonero L, Teixeira T, Poveda E, Plaza Z, Vispo E, Gonzalez-Lahoz J, et al. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos (t) ide analogues. AIDS 2011;25:73-79.
36. Manesis E, Schina M, Le Gal F, Agelopoulou O, Papaioannou C, Kalligeros C, et al. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. Antivir Ther 2007;12:381-388.
37. Wedemeyer H. Re-emerging interest in hepatitis delta: new insights into the dynamic interplay between HBV and HDV. J Hepatol 2010;52:627-629.
38. Maylin S, Boyd A, Lavocat F, Gozlan J, Lascoux-Combe C, Miailhes P, et al. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients. AIDS 2012;26:939-949.
39. Plaza Z, Aguilera A, Mena A, Vispo E, Sierra-Enguita R, Tome S, et al. Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B. AIDS 2013;27:2219-2224.
40. Gudima S, Chang J, Moraleda G, Azvolinsky A, Taylor J. Parameters of human hepatitis delta virus genome replication: the quantity, quality, and intracellular distribution of viral proteins and RNA. J Virol 2002;76:3709-3719.
41. Thompson M, Aberg J, Hoy J, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012;308:387-402.
42. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf [Accessed 20 March 2014].
43. European AIDS Clinical Society (EACS). EACS Guidelines, version 7.0 (October 2013). www.eacs.org [Accessed 20 March 2014].